SPL028 is the Company’s injectable deuterated DMT candidate with multi-layered IP protection The Phase I study aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration of SPL028 LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting…


Previous articlePsychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch from Horizons New York 2022
Next articleNuminus to Participate in Wonderland: Miami on November 3-5, 2022